Advisors to NCI are preparing to recommend a “Human Cancer Genome Project” that would create a comprehensive chart of the genetic mutations that cause cancer. The panel also plans to propose an initiative in molecular diagnostics, Eric Lander, director of the Broad Institute, said.
Also in this 8-page issue: White House appoints Koch Industries executive David Koch to the National Cancer Advisory Board. He asks: “How can we make the NCI elephant dance like a ballerina?”
Funding opportunities listed.
Trending Stories
- Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - With five-year cancer survival at an all-time high, does this mean people are living longer?
- Blood Cancer United: A new name at the right moment
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - In The Headlines: Is early detection always good? Inside NCI’s MCD feasibility trial.
- Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer
